India Seeks To Revive National Vaccine Production Program
This article was originally published in PharmAsia News
Executive Summary
Indian authorities are considering a revival of the nation's vaccine-production program to make up for recent declines due to failures to meet international standards. Two Indian companies lost sanction by the World Health Organization because they failed to meet good manufacturing practices standards. But if the government is to revive vaccine production for bacillus calmetteguerin, cholera, diptheria, rabies, tetanus and typhoid, it may have to invest $5 billion in the effort. Among the suggestions is establishment of state-run manufacturing companies to produce vaccines companies complying with World Health Organization standards. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.